Lung cancer :: New cancer drug AS1404 Antisoma extends life for lung cancer patients
Lung cancer patients treated with an experimental new drug lived over a third longer than patients treated with standard chemotherapy, according to data released. The phase II study, carried out by UK biotech company Antisoma plc, looked at 70 patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer.